Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau

LM Smirnova, E Yu Vertieva, O Yu Olisova, EM AnpilogovaDepartment of Dermatology and Venereology, I.M. Sechenov First Moscow State Medical University, Moscow 119991, Russian FederationBackground: Chronic acrodermatitis continua of Hallopeau (ACH) is a rare form of pustular psoriasis predominantly af...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Smirnova LM, Vertieva EY, Olisova OY, Anpilogova EM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	acrodermatitis continua of Hallopeau secukinumab apremilast anti IL-17A therapy phosphodiesterase-4 Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/04f3d29a72cd4cc19f9bf7ba0c514796
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:04f3d29a72cd4cc19f9bf7ba0c514796
record_format	dspace
spelling	oai:doaj.org-article:04f3d29a72cd4cc19f9bf7ba0c5147962021-12-02T07:32:35ZOutcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau1177-5491https://doaj.org/article/04f3d29a72cd4cc19f9bf7ba0c5147962019-05-01T00:00:00Zhttps://www.dovepress.com/outcomes-of-various-types-of-therapy-in-patients-with-treatment-resist-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491LM Smirnova, E Yu Vertieva, O Yu Olisova, EM AnpilogovaDepartment of Dermatology and Venereology, I.M. Sechenov First Moscow State Medical University, Moscow 119991, Russian FederationBackground: Chronic acrodermatitis continua of Hallopeau (ACH) is a rare form of pustular psoriasis predominantly affecting the distal phalanges of the fingers and toes. The disease manifests by pustular rash with marked infiltration, fissures, and often results into severe dystrophy of nail plates. ACH is refractory to most of psoriasis standard of care (SOC) therapies.Objective: The objective of this study is to assess the prospects of secukinumab therapy of ACH based on current clinical observation.Methods: We observed a female patient with ACH. Number of SOC treatments were applied in that case including local PUVA therapy, systemic retinoids, methotrexate, and biologic agents.Result: Secukinumab, a IL-17 inhibitor, demonstrated pronounced clinical effect in the case of ACH refractory to other SOC therapies.Conclusion: IL-17 inhibition provided by secukinumab was linked to clinically meaningful improvement in the heavily pretreated ACH. Further exploration and clinical studies may be important to provide more data on secukinumab effects in ACH.Keywords: acrodermatitis continua of Hallopeau, secukinumab, apremilast, anti IL-17A therapy, phosphodiesterase-4Smirnova LMVertieva EYOlisova OYAnpilogova EMDove Medical Pressarticleacrodermatitis continua of Hallopeausecukinumabapremilastanti IL-17A therapyphosphodiesterase-4Medicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 13, Pp 83-87 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	acrodermatitis continua of Hallopeau secukinumab apremilast anti IL-17A therapy phosphodiesterase-4 Medicine (General) R5-920
spellingShingle	acrodermatitis continua of Hallopeau secukinumab apremilast anti IL-17A therapy phosphodiesterase-4 Medicine (General) R5-920 Smirnova LM Vertieva EY Olisova OY Anpilogova EM Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau
description	LM Smirnova, E Yu Vertieva, O Yu Olisova, EM AnpilogovaDepartment of Dermatology and Venereology, I.M. Sechenov First Moscow State Medical University, Moscow 119991, Russian FederationBackground: Chronic acrodermatitis continua of Hallopeau (ACH) is a rare form of pustular psoriasis predominantly affecting the distal phalanges of the fingers and toes. The disease manifests by pustular rash with marked infiltration, fissures, and often results into severe dystrophy of nail plates. ACH is refractory to most of psoriasis standard of care (SOC) therapies.Objective: The objective of this study is to assess the prospects of secukinumab therapy of ACH based on current clinical observation.Methods: We observed a female patient with ACH. Number of SOC treatments were applied in that case including local PUVA therapy, systemic retinoids, methotrexate, and biologic agents.Result: Secukinumab, a IL-17 inhibitor, demonstrated pronounced clinical effect in the case of ACH refractory to other SOC therapies.Conclusion: IL-17 inhibition provided by secukinumab was linked to clinically meaningful improvement in the heavily pretreated ACH. Further exploration and clinical studies may be important to provide more data on secukinumab effects in ACH.Keywords: acrodermatitis continua of Hallopeau, secukinumab, apremilast, anti IL-17A therapy, phosphodiesterase-4
format	article
author	Smirnova LM Vertieva EY Olisova OY Anpilogova EM
author_facet	Smirnova LM Vertieva EY Olisova OY Anpilogova EM
author_sort	Smirnova LM
title	Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau
title_short	Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau
title_full	Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau
title_fullStr	Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau
title_full_unstemmed	Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau
title_sort	outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of hallopeau
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/04f3d29a72cd4cc19f9bf7ba0c514796
work_keys_str_mv	AT smirnovalm outcomesofvarioustypesoftherapyinpatientswithtreatmentresistantacrodermatitiscontinuaofhallopeau AT vertievaey outcomesofvarioustypesoftherapyinpatientswithtreatmentresistantacrodermatitiscontinuaofhallopeau AT olisovaoy outcomesofvarioustypesoftherapyinpatientswithtreatmentresistantacrodermatitiscontinuaofhallopeau AT anpilogovaem outcomesofvarioustypesoftherapyinpatientswithtreatmentresistantacrodermatitiscontinuaofhallopeau
_version_	1718399319261839360

Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau

Ejemplares similares